Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)


 0.02 (0.30%)

Market Cap$70,178,077

02/16/18  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $6.60 with a 52 week high of $21.59 and a 52 week low of $6.07.

Gemphire Announces Pricing of $22 Million Public Offering of Common Stock


Read More

Gemphire Announces Proposed Public Offering of Common Stock


Read More

Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)


Read More

There are currently no events scheduled.